Severe sinus bradycardia associated with favipiravir in a COVID‐19 patient
Open Access
- 6 August 2021
- journal article
- case report
- Published by Wiley in Clinical Case Reports
- Vol. 9 (8) , e04566
Abstract
The antiviral medication “favipiravir” should be considered as a possible cause of unexplained sinus bradycardia.Keywords
This publication has 11 references indexed in Scilit:
- Role of favipiravir in the treatment of COVID-19International Journal of Infectious Diseases, 2021
- Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control StudyEngineering, 2020
- Arrhythmia in COVID-19SN Comprehensive Clinical Medicine, 2020
- AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical TrialClinical Infectious Diseases, 2020
- Bradycardia in Patients With COVID-19: A Calm Before the Storm?Cureus, 2020
- Clinical analysis of sinus bradycardia in patients with severe COVID-19 pneumoniaCritical Care, 2020
- 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction DelayJACC, 2019
- Corticosteroid-induced bradycardiaCanadian Pharmacists Journal / Revue des Pharmaciens du Canada, 2015
- Cardiovascular adverse effects of metoclopramide: Review of literatureInternational Journal of Case Reports and Images, 2012
- A method for estimating the probability of adverse drug reactionsClinical Pharmacology & Therapeutics, 1981